INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Data sources
SEC FORM 421m ago
HOUSE PTR20m ago
SEC 13F20m ago
ROBINHOOD CHAIN20m ago
Public company

ALNYALNYLAM PHARMACEUTICALS, INC.

CIK 0001178670

EDGAR filingsOpen in network
Disclosed transactions60
Buys / sells0 / 57
Max Insider Score39
Connections12with evidence

ALNY · disclosed activity on price

Disclosed transactions

ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
36
TT
Tanguler TolgaEVP, Chief Commercial Officer
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale
SELL$17K
47 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC FORM 4

Evidence

Verified connections

  • In industryevidence
    Pharmaceuticals, devices & health servicesSEC SIC 2834 · Pharmaceutical Preparations · Nov 4, 2026
  • ← Connected organizationevidence
    ALNYLAM PHARMACEUTICALS, INC. POLITICAL ACTION COMMITTEE (ALNYLAM PAC)FEC Form 1 connected organization: ALNYLAM PHARMACEUTICALS, INC. (exact legal-name match) · Nov 4, 2026
  • ← Lobbied forevidence
    LMH STRATEGIC SOLUTIONSLDA Q2 2026 second quarter · Medicare/Medicaid · Aug 26, 2026
  • ← Lobbied forevidence
    TIBER CREEK GROUPLDA Q1 2026 first quarter · Medicare/Medicaid · Aug 26, 2026
  • ← Lobbied for
36
GP
Garg PushkalEVP Chief R&D
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale
SELL
$14K
39 sh
Jan 12, 2026
Jan 14, 2026
traded Jan 12, 2026
+2d
SEC FORM 4

Evidence

29
GY
Greenstreet YvonneDirector, Chief Executive Officer
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale
SELL$44K
118 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC FORM 4

Evidence

20
FJ
Fitzgerald Kevin JosephCSO & EVP, Head of Research
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$7,047
19 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC FORM 4

Evidence

36
TT
Tanguler TolgaEVP, Chief Commercial Officer
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale
SELL$34K
92 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC FORM 4

Evidence

19
PV
Poulton Jeffrey V.EVP, Chief Financial Officer
ALNYALNYLAM PHARMACEUTICALS, INC.
Grant or award
A—
6,193 sh
Jan 11, 2026Jan 14, 2026
traded Jan 11, 2026
+3dSEC FORM 4

Evidence

20
FJ
Fitzgerald Kevin JosephCSO & EVP, Head of Research
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$15K
40 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC FORM 4

Evidence

36
TT
Tanguler TolgaEVP, Chief Commercial Officer
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale
SELL$15K
41 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC FORM 4

Evidence

20
FJ
Fitzgerald Kevin JosephCSO & EVP, Head of Research
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$34K
92 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC FORM 4

Evidence

39
PV
Poulton Jeffrey V.EVP, Chief Financial Officer
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale
SELL$148K
405 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC FORM 4

Evidence

16
FJ
Fitzgerald Kevin JosephCSO & EVP, Head of Research
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$72K
197 sh
Jan 13, 2026Jan 14, 2026
traded Jan 13, 2026
+1dSEC FORM 4

Evidence

36
TT
Tanguler TolgaEVP, Chief Commercial Officer
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale
SELL$15K
40 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC FORM 4

Evidence

13
FJ
Fitzgerald Kevin JosephCSO & EVP, Head of Research
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$46K
122 sh
Jan 13, 2026Jan 14, 2026
traded Jan 13, 2026
+1dSEC FORM 4

Evidence

16
FJ
Fitzgerald Kevin JosephCSO & EVP, Head of Research
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$104K
280 sh
Jan 13, 2026Jan 14, 2026
traded Jan 13, 2026
+1dSEC FORM 4

Evidence

23
FJ
Fitzgerald Kevin JosephCSO & EVP, Head of Research
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$56K
155 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC FORM 4

Evidence

20
FJ
Fitzgerald Kevin JosephCSO & EVP, Head of Research
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$17K
47 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC FORM 4

Evidence

20
FJ
Fitzgerald Kevin JosephCSO & EVP, Head of Research
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$26K
73 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC FORM 4

Evidence

20
FJ
Fitzgerald Kevin JosephCSO & EVP, Head of Research
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$35K
98 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC FORM 4

Evidence

23
FJ
Fitzgerald Kevin JosephCSO & EVP, Head of Research
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$80K
220 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC FORM 4

Evidence

23
FJ
Fitzgerald Kevin JosephCSO & EVP, Head of Research
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$73K
199 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC FORM 4

Evidence

20
FJ
Fitzgerald Kevin JosephCSO & EVP, Head of Research
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$15K
41 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC FORM 4

Evidence

20
FJ
Fitzgerald Kevin JosephCSO & EVP, Head of Research
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$18K
50 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC FORM 4

Evidence

20
FJ
Fitzgerald Kevin JosephCSO & EVP, Head of Research
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$5,242
14 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC FORM 4

Evidence

20
FJ
Fitzgerald Kevin JosephCSO & EVP, Head of Research
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$745
2 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC FORM 4

Evidence

20
FJ
Fitzgerald Kevin JosephCSO & EVP, Head of Research
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$5,667
15 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC FORM 4

Evidence

20
FJ
Fitzgerald Kevin JosephCSO & EVP, Head of Research
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$7,137
19 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC FORM 4

Evidence

16
FJ
Fitzgerald Kevin JosephCSO & EVP, Head of Research
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$238K
644 sh
Jan 13, 2026Jan 14, 2026
traded Jan 13, 2026
+1dSEC FORM 4

Evidence

16
FJ
Fitzgerald Kevin JosephCSO & EVP, Head of Research
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$207K
562 sh
Jan 13, 2026Jan 14, 2026
traded Jan 13, 2026
+1dSEC FORM 4

Evidence

16
FJ
Fitzgerald Kevin JosephCSO & EVP, Head of Research
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$180K
485 sh
Jan 13, 2026Jan 14, 2026
traded Jan 13, 2026
+1dSEC FORM 4

Evidence

36
GP
Garg PushkalEVP Chief R&D
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale
SELL$15K
41 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC FORM 4

Evidence

36
GP
Garg PushkalEVP Chief R&D
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale
SELL$34K
92 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC FORM 4

Evidence

36
TT
Tanguler TolgaEVP, Chief Commercial Officer
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale
SELL$44K
123 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC FORM 4

Evidence

36
TT
Tanguler TolgaEVP, Chief Commercial Officer
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale
SELL$31K
85 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC FORM 4

Evidence

39
TT
Tanguler TolgaEVP, Chief Commercial Officer
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale
SELL$56K
155 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC FORM 4

Evidence

36
TT
Tanguler TolgaEVP, Chief Commercial Officer
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale
SELL$35K
98 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC FORM 4

Evidence

36
TT
Tanguler TolgaEVP, Chief Commercial Officer
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale
SELL$26K
73 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC FORM 4

Evidence

39
TT
Tanguler TolgaEVP, Chief Commercial Officer
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale
SELL$73K
199 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC FORM 4

Evidence

39
TT
Tanguler TolgaEVP, Chief Commercial Officer
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale
SELL$80K
220 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC FORM 4

Evidence

36
TT
Tanguler TolgaEVP, Chief Commercial Officer
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale
SELL$745
2 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC FORM 4

Evidence

36
TT
Tanguler TolgaEVP, Chief Commercial Officer
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale
SELL$5,242
14 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC FORM 4

Evidence

36
GP
Garg PushkalEVP Chief R&D
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale
SELL$31K
85 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC FORM 4

Evidence

39
GP
Garg PushkalEVP Chief R&D
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale
SELL$56K
155 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC FORM 4

Evidence

36
GP
Garg PushkalEVP Chief R&D
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale
SELL$35K
98 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC FORM 4

Evidence

39
GP
Garg PushkalEVP Chief R&D
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale
SELL$80K
220 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC FORM 4

Evidence

36
GP
Garg PushkalEVP Chief R&D
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale
SELL$18K
50 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC FORM 4

Evidence

36
GP
Garg PushkalEVP Chief R&D
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale
SELL$15K
41 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC FORM 4

Evidence

36
GP
Garg PushkalEVP Chief R&D
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale
SELL$7,137
19 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC FORM 4

Evidence

32
GY
Greenstreet YvonneDirector, Chief Executive Officer
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale
SELL$168K
464 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC FORM 4

Evidence

32
GY
Greenstreet YvonneDirector, Chief Executive Officer
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale
SELL$116K
316 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC FORM 4

Evidence

32
GY
Greenstreet YvonneDirector, Chief Executive Officer
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale
SELL$96K
261 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC FORM 4

Evidence

32
GY
Greenstreet YvonneDirector, Chief Executive Officer
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale
SELL$215K
584 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC FORM 4

Evidence

29
GY
Greenstreet YvonneDirector, Chief Executive Officer
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale
SELL$36K
94 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC FORM 4

Evidence

39
PV
Poulton Jeffrey V.EVP, Chief Financial Officer
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale
SELL$133K
365 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC FORM 4

Evidence

36
PV
Poulton Jeffrey V.EVP, Chief Financial Officer
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale
SELL$2,235
6 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC FORM 4

Evidence

36
PV
Poulton Jeffrey V.EVP, Chief Financial Officer
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale
SELL$13K
34 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC FORM 4

Evidence

36
PV
Poulton Jeffrey V.EVP, Chief Financial Officer
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale
SELL$10K
27 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC FORM 4

Evidence

19
TT
Tanguler TolgaEVP, Chief Commercial Officer
ALNYALNYLAM PHARMACEUTICALS, INC.
Grant or award
A—
3,800 sh
Jan 11, 2026Jan 14, 2026
traded Jan 11, 2026
+3dSEC FORM 4

Evidence

9
FJ
Fitzgerald Kevin JosephCSO & EVP, Head of Research
ALNYALNYLAM PHARMACEUTICALS, INC.
Grant or award · 10b5-1 plan
A—
3,800 sh
Jan 11, 2026Jan 14, 2026
traded Jan 11, 2026
+3dSEC FORM 4

Evidence

20
FJ
Fitzgerald Kevin JosephCSO & EVP, Head of Research
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$14K
39 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC FORM 4

Evidence

35
GY
Greenstreet YvonneDirector, Chief Executive Officer
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale
SELL$510K
1,395 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC FORM 4

Evidence

evidence
TODD STRATEGY GROUP
LDA Q1 2026 first quarter · Medicare/Medicaid · Aug 26, 2026
  • ← Lobbied forevidence
    CAPITOL COUNSEL LLCLDA Q2 2026 second quarter · MED · Aug 26, 2026
  • ← Lobbied forevidence
    SPLITOAK STRATEGIES LLCLDA Q2 2026 second quarter · Medicare/Medicaid · Aug 26, 2026
  • ← Insider ofevidence
    Garg PushkalEVP Chief R&D · Jan 14, 2026
  • ← Insider ofevidence
    Fitzgerald Kevin JosephCSO & EVP, Head of Research · Jan 14, 2026
  • ← Insider ofevidence
    Poulton Jeffrey V.EVP, Chief Financial Officer · Jan 14, 2026
  • ← Insider ofevidence
    Tanguler TolgaEVP, Chief Commercial Officer · Jan 14, 2026
  • ← Insider ofevidence
    Greenstreet YvonneDirector, Chief Executive Officer · Nov 14, 2025

    • Lobbying

    $880K reported · de-duplicated
    2026 Q2 $450K in-house2026 Q1 $430K in-house
    • TODD STRATEGY GROUP$60K2026 Q2 · posted Aug 26, 2026 · Medicare/Medicaid
    • SPLITOAK STRATEGIES LLC$60K2026 Q1 · posted Aug 26, 2026 · Medicare/Medicaid
    • CAPITOL COUNSEL LLC$60K2026 Q1 · posted Aug 26, 2026 · MED
    • In-house report$430K2026 Q1 · posted Aug 26, 2026 · Medicare/Medicaid, Trade, Pharmacy
    • In-house report$450K2026 Q2 · posted Aug 26, 2026 · Pharmacy, Medicare/Medicaid, Trade
    • LMH STRATEGIC SOLUTIONS$50K2026 Q1 · posted Aug 26, 2026 · Medicare/Medicaid
    • TIBER CREEK GROUP$60K2026 Q2 · posted Aug 26, 2026 · Medicare/Medicaid
    • TIBER CREEK GROUP$60K2026 Q1 · posted Aug 26, 2026 · Medicare/Medicaid
    • TODD STRATEGY GROUP$60K2026 Q1 · posted Aug 26, 2026 · Medicare/Medicaid
    • LMH STRATEGIC SOLUTIONS$50K2026 Q2 · posted Aug 26, 2026 · Medicare/Medicaid
    • CAPITOL COUNSEL LLC$30K2026 Q2 · posted Aug 26, 2026 · MED
    • SPLITOAK STRATEGIES LLC$60K2026 Q2 · posted Aug 26, 2026 · Medicare/Medicaid

    Connected PAC contributions

    FEC · direct to members
    • John JoyceR$10KALNYLAM PHARMACEUTICALS, INC. POLITICAL ACTION COMMITTEE (ALNYLAM PAC)
    • Richard HudsonR$10KALNYLAM PHARMACEUTICALS, INC. POLITICAL ACTION COMMITTEE (ALNYLAM PAC)
    • Donald G. DavisD$8,500ALNYLAM PHARMACEUTICALS, INC. POLITICAL ACTION COMMITTEE (ALNYLAM PAC)
    • Brett GuthrieR$8,000ALNYLAM PHARMACEUTICALS, INC. POLITICAL ACTION COMMITTEE (ALNYLAM PAC)
    • Mariannette Miller-MeeksR$7,500
    ALNYLAM PHARMACEUTICALS, INC. POLITICAL ACTION COMMITTEE (ALNYLAM PAC)
  • Lloyd SmuckerR$6,000ALNYLAM PHARMACEUTICALS, INC. POLITICAL ACTION COMMITTEE (ALNYLAM PAC)
  • Thomas H. Kean, Jr.R$6,000ALNYLAM PHARMACEUTICALS, INC. POLITICAL ACTION COMMITTEE (ALNYLAM PAC)
  • Brittany PettersenD$5,000ALNYLAM PHARMACEUTICALS, INC. POLITICAL ACTION COMMITTEE (ALNYLAM PAC)
  • H. Morgan GriffithR$5,000ALNYLAM PHARMACEUTICALS, INC. POLITICAL ACTION COMMITTEE (ALNYLAM PAC)
  • Jake AuchinclossD$5,000ALNYLAM PHARMACEUTICALS, INC. POLITICAL ACTION COMMITTEE (ALNYLAM PAC)
  • Kevin MullinD$5,000ALNYLAM PHARMACEUTICALS, INC. POLITICAL ACTION COMMITTEE (ALNYLAM PAC)
  • Joseph D. MorelleD$4,000ALNYLAM PHARMACEUTICALS, INC. POLITICAL ACTION COMMITTEE (ALNYLAM PAC)